Intermittent levosimendan treatment in patients with severe congestive heart failure

Clinical Research in Cardiology

Volumn 102, Issue 7, 2013, Pages 485-493

  Tuomainen, Petri O ^a   Magga, Jarkko ^a   Timonen, Pekka ^a   Miettinen, Kati ^a   Kurttila, Minna ^a   Vanninen, Esko ^a   Laitinen, Tomi ^a   Timonen, Kirsi ^a   Punnonen, Kari ^a   Parviainen, Ilkka ^a   Uusaro, Ari ^a   Vuolteenaho, Olli ^b   Kivikko, Matti ^c   Peuhkurinen, Keijo ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c ORION CORPORATION   (Finland)

Author keywords

Heart failure; Levosimendan; Quality of life; Repeated treatment

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LEVOSIMENDAN; NITRATE; NORADRENALIN; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BICYCLE ERGOMETRY; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CARDIOPULMONARY EXERCISE TEST; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; EXERCISE; FEMALE; HEART EJECTION FRACTION; HEART OUTPUT; HEART RATE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMIC MONITORING; HUMAN; LONG TERM CARE; LUNG WEDGE PRESSURE; MALE; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RADIAL ARTERY; STEADY STATE; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT DURATION; WELLBEING;

AGED; CARDIOTONIC AGENTS; DRUG ADMINISTRATION SCHEDULE; EXERCISE TEST; EXERCISE TOLERANCE; HEART FAILURE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXYGEN; PYRIDAZINES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84880268179     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-013-0554-5     Document Type: Article

References (39)

1. Gruhn N, Nielsen-Kudsk JE, Theilgaard S et al (1998) Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 31:741-749
2. Lilleberg J, Nieminen MS, Akkila J et al (1998) Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 19:660-668
3. Kivikko M, Lehtonen L, Colucci WS (2003) Sustained hemodynamic effects of intravenous levosimendan. Circulation 107:81-86
4. McLean AS, Huang SJ, Nalos M, Ting I (2005) Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol 46:830-835
5. Lilleberg J, Laine M, Palkama T et al (2007) Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 9:75-82
6. Moertl D, Berger R, Huelsmann M et al (2005) Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail 7:1156-1163
7. Parissis JT, Panou F, Farmakis D et al (2005) Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 96:423-426
8. 2+ -sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 7:882-887
9. Kyrzopoulos S, Adamopoulos S, Parissis JT et al (2005) Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 99:409-413
10. Kelly RA, Smith TW (1997) Cytokines and cardiac contractile function. Circulation 95:778-781
11. Rauchhaus M, Doehner W, Francis DP et al (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102:3060-3067
12. Mueller C, Laule-Kilian K, Christ A et al (2006) Inflammation and long-term mortality in acute congestive heart failure. Am Heart J 151:845-850
13. Follath F, Cleland JG, Just H et al (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360:196-202
14. Moiseyev VS, Poder P, Andrejevs N et al (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23:1422-1432
15. Mebazaa A, Nieminen MS, Packer M et al (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297:1883-1891
16. Delaney A, Bradford C, McCaffrey J et al (2007) Is there a place for levosimendan in the intensive care unit? Crit Care Resusc 9:290-292
17. de Lissovoy G, Fraeman K, Teerlink JR et al (2010) Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study. Eur J Health Econ 11:185-193
18. Mavrogeni S, Giamouzis G, Papadopoulou E et al (2007) A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail 13:556-559
19. Parle NM, Thomas MD, Dembo L et al (2008) Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience. Heart Lung Circ 17:206-210
20. Nanas JN, Papazoglou P, Tsagalou EP et al (2005) Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol 95:768-771
21. Bonios MJ, Terrovitis JV, Drakos SG et al (2012) Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol 159:225-229
22. Rector TS, Cohn JN (1992) Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 124:1017-1025
23. Rector TS, Kubo SH, Cohn JN (1993) Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 71:1106-1107
24. Miettinen KH, Eriksson S, Magga J et al (2008) Clinical significance of troponin I efflux and troponin autoantibodies in patients with dilated cardiomyopathy. J Card Fail 14:481-488
25. Ala-Kopsala M, Magga J, Peuhkurinen K et al (2004) Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 50:1576-1588
26. Ala-Kopsala M, Ruskoaho H, Leppaluoto J et al (2005) Single assay for amino-terminal fragments of cardiac A- and B-type natriuretic peptides. Clin Chem 51:708-718
27. Mukoyama M, Nakao K, Hosoda K et al (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87:1402-1412
28. Yoshimura M, Yasue H, Okumura K et al (1993) Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87:464-469
29. Parissis JT, Adamopoulos S, Farmakis D et al (2006) Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 92:1768-1772
30. Wollert KC, Drexler H (2001) The role of interleukin-6 in the failing heart. Heart Fail Rev 6:95-103
31. Adamopoulos S, Parissis JT, Iliodromitis EK et al (2006) Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 98:102-106
32. Trikas A, Antoniades C, Latsios G et al (2006) Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail 8:804-809
33. Ceconi C, Curello S, Bachetti T et al (1998) Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium? Prog Cardiovasc Dis 41:25-30
34. Hofmann U, Heuer S, Meder K et al (2007) The proinflammatory cytokines TNF-alpha and IL-1 beta impair economy of contraction in human myocardium. Cytokine 39:157-162
35. Lok DJ, Lok SI, Bruggink-André de la Porte PW et al (2012) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol [Epub ahead of print]
36. Gombos T, Förhécz Z, Pozsonyi Z et al (2012) Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure. Clin Res Cardiol 101:607-615
37. Volz HC, Laohachewin D, Schellberg D et al (2012) HMGB1 is an independent predictor of death and heart transplantation in heart failure. Clin Res Cardiol 101:427-435
38. Flevari P, Parissis JT, Leftheriotis D et al (2006) Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 98:1641-1645
39. Drakos SG, Kanakakis JV, Nanas S et al (2009) Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure. J Cardiovasc Pharmacol 53:157-161